To include your compound in the COVID-19 Resource Center, submit it here.

FDA approves Lilly's Verzenio as first-line endocrine therapy

Eli Lilly and Co. (NYSE:LLY) said FDA approved Verzenio abemaciclib

Read the full 104 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE